Q-omics provides the consensus-scored TTYH1 profile across patient tissues and cancer cell-line models. TTYH1 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, TTYH1 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, TTYH1 RNA expression shows 15,364 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and HNSC as cancer lineages where TTYH1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TTYH1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TTYH1 survival associations across molecular data types. TTYH1 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (5) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TTYH1 RNA expression–survival associations across cancer types. High TTYH1 expression shows unfavorable associations in ACC, KIRC, KIRP, CHOL and THCA, but favorable associations in HNSC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for TTYH1 RNA expression.
This table summarizes TTYH1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for TTYH1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TTYH1 shows lower tumor expression in HNSC, BRCA, UCEC and KICH and higher tumor expression in LUAD and LUSC. The HNSC box plot shows higher TTYH1 RNA expression in normal versus tumor tissue (log2 FC = −0.709, t-test p < 0.001).
This table shows molecular features associated with TTYH1 in patient tissues and cancer cell lines. In patient samples, TTYH1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TTYH1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BONE.
